Novo Nordisk’s chief executive, Mike Doustdar, is a year into a corporate turnaround. He says investors are still underestimating the promise of the company’s drugs.

Source: [New York Times](https://www.nytimes.com/2026/09/01/business/novo-nordisk-ozempic-wegovy-glp1s-stocks.html)

Sponsored